USING AI AND NEUROIMAGING

ADVANCED CLINICAL TRIALS AND THERAPIES

OPTIMIZED THERAPIES

OPTIMAL MEASURES

NEWS

Qynapse to present clinical results of QyScore® for Alzheimer’s Disease and Multiple Sclerosis at the 7th Congress of the European Academy of Neurology

QYNAPSE today announced it will present clinical data on QyScore® for Alzheimer’s disease and multiple sclerosis at the 7th Congress of the European Academy of Neurology (EAN), which is being held virtually on June 19 - 22, 2021. Enrica Cavedo, PhD, Scientific Lead at Qynapse, will give an ePresentation on June 20, 2021, at 6:05 a.m. ET and Philippe Tran, R&D Scientist at Qynapse, will give an ePoster on June 20, 2021, at 1:30 p.m. ET.

Qynapse reaffirms its commitment to research in Multiple Sclerosis and is pleased to announce new projects to advance research and clinical care for MS patients

Qynapse joins the global multiple sclerosis (MS) community in recognition of World MS Day to raise awareness for everyone affected by MS. Emphasizing the World MS Day 2021 theme, MS Connections, Qynapse has been engaged for years in contributing to connect MS patients to MS research, especially in the field of neuroimaging innovation.

QYNAPSE to Present at Sachs 4th Annual Neuroscience Innovation Forum

QYNAPSE is pleased to participate in the Sachs 4th Annual Neuroscience Innovation Forum (#Sachs_NIF) on April 28-30, 2021. Olivier Courrèges, CEO of QYNAPSE, is pleased to present QYNAPSE’s corporate vision on Day 1 of the Sachs 4th Annual Neuroscience Innovation Forum – which will be held virtually on Wednesday, April 28, 2021 at 2:20 p.m. ET.

Qynapse joins Decentralized Trials & Research Alliance (DTRA) to democratize and accelerate clinical trials

QYNAPSE joins a historic alliance of fifty life sciences and healthcare organizations that seeks to accelerate the broad adoption of patient-focused, decentralized clinical trials and research. DTRA plans to unite industry stakeholders to make clinical trial participation widely accessible by advancing policies, research practices and new technologies in decentralized clinical research.

Qynapse is a medical technology company, spin-off of the CATI consortium of neuroimaging research laboratories.

Qynapse is a medical technology company, spin-off of the CATI consortium of neuroimaging research laboratories.

OUR CLIENTS

OUR CLIENTS

PHARMAS

A solution for supporting the data-driven selection of patients, monitoring drug performance and assessing the clinical trials outcomes.

HEALTHCARE PROVIDERS

A solution that offers early and extensive insights to assist in personalizing therapies for improved patient care.